Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera-Reference-Cited by-同舟云学术

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Published:2015-10-08 Issue:15 Volume:126 Page:1762-1769
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Gisslinger Heinz¹,Zagrijtschuk Oleh²,Buxhofer-Ausch Veronika³⁴,Thaler Josef⁵,Schloegl Ernst⁶,Gastl Guenther A.⁷,Wolf Dominik⁷⁸,Kralovics Robert¹⁹,Gisslinger Bettina¹,Strecker Karin³,Egle Alexander¹⁰,Melchardt Thomas¹⁰,Burgstaller Sonja⁵,Willenbacher Ella⁷,Schalling Martin¹,Them Nicole C.⁹,Kadlecova Pavla¹¹,Klade Christoph²,Greil Richard¹⁰

Affiliation:

1. Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria;

2. AOP Orphan Pharmaceuticals AG, Vienna, Austria;

3. Sozialmedizinisches Zentrum Ost - Donauspital, Vienna, Austria;

4. Krankenhaus der Elisabethinen Linz, Linz, Austria;

5. Department of Internal Medicine IV, Wels-Grieskirchen Hospital, Wels, Austria;

6. Third Medical Department, Hanusch Hospital, Vienna, Austria;

7. Department of Internal Medicine V, Hematology & Oncology, Innsbruck Medical University, Innsbruck, Austria;

8. Medical Clinic 3, Oncology, Hematology and Rheumatology, University Hospital of Bonn, Bonn, Germany;

9. Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;

10. Laboratory for Immunological and Molecular Cancer Research, Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; and

11. Advanced Drug and Device Services SAS, Brno, Czech Republic

Abstract

Key Points The novel IFNα-2b, ropeginterferon alfa-2b, administered once every 2 weeks has low toxicity and induces high and sustained response rates in polycythemia vera patients. Ropeginterferon alfa-2b induces significant partial and complete molecular response rates, as reflected by reduction of JAK2 allelic burden.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/15/1762/1389382/1762.pdf

Reference26 articles.

1. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].;Linkesch;Acta Med Austriaca,1985

2. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases.;Gisslinger;Lancet,1989

3. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.;Silver;Cancer,2006

4. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera.;Heis;Eur J Haematol,1999

5. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.;Baxter;Lancet,2005

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management;American Journal of Hematology;2024-01-25

2. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes;Annals of Hematology;2023-12-07

3. Polycythemia Vera: Barriers to and Strategies for Optimal Management;Blood and Lymphatic Cancer: Targets and Therapy;2023-12

4. Moving toward disease modification in polycythemia vera;Blood;2023-11-30

5. A Perspective of the Amide Group Containing FDA Approved Anticancer Drugs from 2021–2022 (A Review);Russian Journal of Bioorganic Chemistry;2023-11